Prof. Dr. Christian Burholt LL.M., Author at Global Compliance News

Author

Prof. Dr. Christian Burholt LL.M.

Browsing

Prof. Dr. Christian Burholt is a partner in the Firm's Berlin office. He has more than 18 years of experience representing German and international clients in antitrust, leniency, dominance, and merger control law matters. In addition, he is Head of the Firm's German Healthcare & Life Sciences Industry Group and member of the EMEA Healthcare & Life Sciences Steering Committee. Christian has been consistently recommended in various legal directories, including JUVE, Handelsblatt/Best Lawyers in Germany, Legal 500, Expert Guides Life Sciences and Who’s Who Legal, for his antitrust, merger control, pharma, medtech and healthcare work. Christian is admitted to the Berlin bar and a member of the German Association of Antitrust Lawyers and the Network Compliance. He is an honorary professor for antitrust law at the Berlin School of Economics and Law (Hochschule für Wirtschaft und Recht Berlin) and regularly lectures and publishes on antitrust and merger control topics.

In Antitrust / Competition

Germany/Europe: Current Developments in German and European Antitrust Law

August 12, 2022 by Dr. Nicolas Kredel LL.M., Prof. Dr. Christian Burholt LL.M., Katharina Spenner LL.M., Dr. Anika Schürmann LL.M., Dr. Jonas Brueckner, Jan Kresken LL.M., Dr. Steffen Scheuer, Prof. Dr. Michael Schmidl LL.M. Eur., Anahita Thoms LL.M., Katja Häferer, Dr. Jakub Lorys, Florian Tannen, Nina Niejahr and Dr. Alexander Ehrle LL.M. 1 Min Read

On 21 September 2022, colleagues from the German Baker McKenzie offices will host a webinar exploring current developments in German and European Antitrust Law. The event will be in German only.

In Product Regulation & Liability

Germany: German government announces bill to drastically slash drug reimbursement

July 19, 2022 by Dr. Frank Pflüger, Dr. Martin Altschwager LL.M. and Prof. Dr. Christian Burholt LL.M. 7 Mins Read

On 8 July 2022, the German Health Ministry officially shared the second edition of a new bill referred to as the Act for Financial Stability of the Public Health Insurance (GKV-Finanzstabilisierungsgesetz). The bill is still subject to discussions with stakeholders and several rounds of congress hearings. If ultimately implemented, which is a likely scenario, pharma companies will face several painful cutbacks on the statutory reimbursement of prescription-only medicinal products.

In Antitrust / Competition

Europe: Recent Developments in German and European Antitrust Law

April 27, 2022 by Dr. Nicolas Kredel LL.M., Prof. Dr. Christian Burholt LL.M., Katharina Spenner LL.M., Dr. Anika Schürmann LL.M., Anahita Thoms LL.M., Kurt Haegeman, Samantha J. Mobley, Jeffrey (Jeff) D. Martino, Mark Hamer, Jan Kresken LL.M. and Paulo Casagrande 1 Min Read

In this event, we will give you a comprehensive overview of the most important developments of the last year in German and European antitrust law. Please note that this event will be held in German only.